Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06352190
Other study ID # SY-5007-I-04
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date May 1, 2024
Est. completion date June 1, 2024

Study information

Verified date December 2023
Source Shouyao Holdings (Beijing) Co. LTD
Contact Yinghui Sun, PhD
Phone 86-10-88858616
Email yhsun@centaurusbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, open-label, non-randomized, single dose study in healthy male subjects designed to assess mass balance recovery, metabolite profile and metabolite identification of radio-labeled SY-5007 administered orally.


Description:

The trial will consist of two parts: Pilot Study: Two eligible adult male subjects will be enrolled and admitted to the clinical trial center after passing the inclusion criteria review. They will undergo training on medication administration, urine and feces collection, etc., to ensure compliance with the protocol and standard operating procedures (SOP). Subjects will fast before medication administration and provide urine and feces samples at specified intervals after dosing. Blood samples will also be collected at specified time points. Formal Study: Four to six male subjects will be enrolled, receiving a single dose of SY-5007 160 mg orally containinig roughly 120 µCi [14C] SY-5007. Blood, urine and feces samples will be collected at specified time points. Safety monitoring (12-lead ECG, vital signs, blood chemistry and haematology) and adverse events will be monitored throughout the study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 8
Est. completion date June 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: Subjects must meet all of the following criteria to be enrolled in this study: 1. Fully informed, able to communicate effectively with researchers, agree to abide by the protocol and trial management regulations, and voluntarily sign the written Informed Consent Form (ICF); 2. Healthy adult males aged 18 to 50 years at the time of signing the ICF, with no plans for reproduction or sperm donation within the past 2 years; 3. Weight = 50 kg and body mass index (BMI) between 18 and 26 kg/m2; 4. Subjects of reproductive capability agree to employ effective contraceptive measures with their sexual partners during the study period and for 2 years following the end of the study. Exclusion Criteria: Subjects meeting any of the following criteria are ineligible for participation in this study: 1. History of allergies (such as allergies to two or more drugs, foods, or pollen, or individuals prone to skin hives or allergic reactions). 2. Positive for hepatitis B surface antigen, hepatitis C virus antibodies, human immunodeficiency virus antibodies, or positive for syphilis treponemal and non-treponemal antibodies during screening. 3. Abnormal clinically significant vital signs, physical examinations, laboratory tests, or electrocardiograms at screening. 4. Gastrointestinal, hepatic, or renal diseases that may affect drug pharmacokinetics as assessed by the investigator at screening. 5. History of drug abuse or illicit drug use within 12 months prior to the first dose administration, or positive urine drug screening test during screening. 6. Underwent major surgery within 6 months prior to the first dose administration, or planned to undergo surgery during the trial period. 7. History of any clinically significant illness within 3 months prior to the first dose administration or conditions deemed by the investigator to potentially affect trial outcomes, including but not limited to cardiovascular, endocrine, nervous, respiratory, digestive, urinary, hematologic, immune, or psychiatric disorders. 8. Average daily smoking of more than 5 cigarettes within 3 months prior to the first dose administration, or unwillingness to discontinue use of any tobacco products during the trial. 9. Regular alcohol consumption within 3 months prior to the first dose administration [defined as consuming more than 14 units of alcohol per week (1 unit = 360mL of 5% alcohol beer or 45mL of 40% alcohol liquor or 150mL of 12% alcohol wine)], or inability to abstain from alcohol during the trial, or positive alcohol breath test during screening. 10. History of blood donation or significant blood loss (= 300mL) within 3 months prior to the first dose administration, or use of blood products or blood transfusion within 1 month prior to the first dose administration. 11. Participation in other drug or medical device clinical trials within 3 months prior to the first dose administration (excluding screen failures), or prior use of the investigational drug. 12. Vaccination within 1 month prior to the first dose administration. 13. Use of any prescription drugs, over-the-counter drugs, supplements, or herbal remedies within 2 weeks prior to the first dose administration (if the half-life [t1/2] of the drug can be confirmed, a washout period of 5 times of t1/2 is required). 14. Habitual consumption of more than 8 cups (1 cup = 250mL) of tea, coffee, or caffeinated beverages and unable to abstain from consumption within 48 hours prior to the first dose administration and during the trial. 15. Special dietary requirements or difficulty swallowing. 16. Habitual constipation or previous difficulty with bowel movements. 17. Difficulty with blood collection, history of fainting with needles, or intolerance to venipuncture. 18. Engagement in occupations requiring prolonged exposure to radioactive conditions; or significant exposure to radiation within 1 year prior to the trial (e.g., 2 chest/abdominal CT scans, or 3 other types of X-ray examinations). 19. History of definite neurological or psychiatric disorders, including dementia or seizures diagnosed for any reason. 20. Other conditions deemed unsuitable for participation in this study by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
[14C] SY-5007
Carbon-14 labeled SY-5007

Locations

Country Name City State
China Beijing Friendship Hospital, Capital Medical University Beijing

Sponsors (1)

Lead Sponsor Collaborator
Shouyao Holdings (Beijing) Co. LTD

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total radioactivity in plasma PK: Cmax Highest radioactivity observed plasma concentration At pre-dose and up to 2 weeks post-dose
Primary Total radioactivity in plasma PK: Tmax Time to reach the Cmax At pre-dose and up to 2 weeks post-dose
Primary Total radioactivity in plasma PK: AUC0-t Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration At pre-dose and up to 2 weeks post-dose
Primary Total radioactivity in plasma PK: t½ Defined as apparent plasma terminal phase disposition half-life At pre-dose and up to 2 weeks post-dose
Primary Total radioactivity in plasma PK: CL/F Defined as apparent total body clearance At pre-dose and up to 2 weeks post-dose
Primary Whole blood to plasma total radioactivity ratio To evaluate the extent of distribution of total radioactivity into blood cells At pre-dose and up to 2 weeks post-dose
Primary Cumulative total radioactivity in urine and faeces Mass balance recovery of total radioactivity in all (urine, faeces) amount excreted (Ae) expressed as a percentage of the administered dose (%Ae) At pre-dose and up to 2 weeks post-dose
Primary Metabolic profiling in plasma, urinary and fecal excretion To characterize the metabolic profile and identify circulating and excreted metabolites of SY-5007 using liquid chromatography with mass spectral detection. At pre-dose and up to 2 weeks post-dose
Secondary Cmax of SY-5007 and its metabolites Defined as maximum observed plasma concentration At pre-dose and up to 2 weeks post-dose
Secondary Tmax of SY-5007 and its metabolites Defined as time to maximum plasma concentration At pre-dose and up to 2 weeks post-dose
Secondary AUC0-t of SY-5007 and its metabolites Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration At pre-dose and up to 2 weeks post-dose
Secondary t½ of SY-5007 and its metabolites Defined as apparent plasma terminal phase disposition half-life At pre-dose and up to 2 weeks post-dose
Secondary CL/F of SY-5007 and its metabolites Defined as apparent total body clearance At pre-dose and up to 2 weeks post-dose
Secondary Incidence of adverse events To evaluate the safety of a single oral dose of 160 mg of SY-5007 At pre-dose and up to 2 weeks post-dose
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1